Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1979 3
1980 2
1981 1
1984 1
1985 1
1986 1
1987 4
1988 1
1989 1
1990 4
1991 1
1992 1
1993 4
1994 14
1995 12
1996 14
1997 14
1998 7
1999 17
2000 21
2001 25
2002 33
2003 38
2004 36
2005 43
2006 56
2007 50
2008 27
2009 40
2010 46
2011 49
2012 43
2013 40
2014 36
2015 25
2016 29
2017 26
2018 45
2019 51
2020 48
2021 40
2022 34
Text availability
Article attribute
Article type
Publication date

Search Results

885 results
Results by year
Filters applied: . Clear all
Page 1
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Van Mieghem NM, Unverdorben M, Hengstenberg C, Möllmann H, Mehran R, López-Otero D, Nombela-Franco L, Moreno R, Nordbeck P, Thiele H, Lang I, Zamorano JL, Shawl F, Yamamoto M, Watanabe Y, Hayashida K, Hambrecht R, Meincke F, Vranckx P, Jin J, Boersma E, Rodés-Cabau J, Ohlmann P, Capranzano P, Kim HS, Pilgrim T, Anderson R, Baber U, Duggal A, Laeis P, Lanz H, Chen C, Valgimigli M, Veltkamp R, Saito S, Dangas GD; ENVISAGE-TAVI AF Investigators. Van Mieghem NM, et al. Among authors: boersma e. N Engl J Med. 2021 Dec 2;385(23):2150-2160. doi: 10.1056/NEJMoa2111016. Epub 2021 Aug 28. N Engl J Med. 2021. PMID: 34449183 Clinical Trial.
Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.
Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, Domanski MJ, Farkouh ME, Flather M, Fuster V, Hlatky MA, Holm NR, Hueb WA, Kamalesh M, Kim YH, Mäkikallio T, Mohr FW, Papageorgiou G, Park SJ, Rodriguez AE, Sabik JF 3rd, Stables RH, Stone GW, Serruys PW, Kappetein AP. Head SJ, et al. Among authors: boersma e. Lancet. 2018 Mar 10;391(10124):939-948. doi: 10.1016/S0140-6736(18)30423-9. Epub 2018 Feb 23. Lancet. 2018. PMID: 29478841 Free article. Review.
Understanding of interaction (subgroup) analysis in clinical trials.
Brankovic M, Kardys I, Steyerberg EW, Lemeshow S, Markovic M, Rizopoulos D, Boersma E. Brankovic M, et al. Among authors: boersma e. Eur J Clin Invest. 2019 Aug;49(8):e13145. doi: 10.1111/eci.13145. Epub 2019 Jun 14. Eur J Clin Invest. 2019. PMID: 31135965 Review.
Sex differences in cardiovascular risk factors and disease prevention.
Appelman Y, van Rijn BB, Ten Haaf ME, Boersma E, Peters SA. Appelman Y, et al. Among authors: boersma e. Atherosclerosis. 2015 Jul;241(1):211-8. doi: 10.1016/j.atherosclerosis.2015.01.027. Epub 2015 Jan 28. Atherosclerosis. 2015. PMID: 25670232 Review.
Effectiveness of insertion and maintenance bundles to prevent central-line-associated bloodstream infections in critically ill patients of all ages: a systematic review and meta-analysis.
Ista E, van der Hoven B, Kornelisse RF, van der Starre C, Vos MC, Boersma E, Helder OK. Ista E, et al. Among authors: boersma e. Lancet Infect Dis. 2016 Jun;16(6):724-734. doi: 10.1016/S1473-3099(15)00409-0. Epub 2016 Feb 18. Lancet Infect Dis. 2016. PMID: 26907734 Review.
Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC).
Roos-Hesselink J, Baris L, Johnson M, De Backer J, Otto C, Marelli A, Jondeau G, Budts W, Grewal J, Sliwa K, Parsonage W, Maggioni AP, van Hagen I, Vahanian A, Tavazzi L, Elkayam U, Boersma E, Hall R. Roos-Hesselink J, et al. Among authors: boersma e. Eur Heart J. 2019 Dec 14;40(47):3848-3855. doi: 10.1093/eurheartj/ehz136. Eur Heart J. 2019. PMID: 30907409 Free article.
The legacy of HOPE-3.
Boersma E, Kardys I. Boersma E, et al. Eur Heart J. 2021 Aug 17;42(31):3008-3010. doi: 10.1093/eurheartj/ehab208. Eur Heart J. 2021. PMID: 33956954 No abstract available.
Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial.
Van Mieghem NM, Unverdorben M, Valgimigli M, Mehran R, Boersma E, Baber U, Hengstenberg C, Shi M, Chen C, Saito S, Veltkamp R, Vranckx P, Dangas GD. Van Mieghem NM, et al. Among authors: boersma e. Am Heart J. 2018 Nov;205:63-69. doi: 10.1016/j.ahj.2018.07.006. Epub 2018 Aug 29. Am Heart J. 2018. PMID: 30172099 Clinical Trial.
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).
Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D; ESC Committee for Practice Guidelines. Hamm CW, et al. Among authors: boersma e. Eur Heart J. 2011 Dec;32(23):2999-3054. doi: 10.1093/eurheartj/ehr236. Epub 2011 Aug 26. Eur Heart J. 2011. PMID: 21873419 No abstract available.
Plasma markers in pulmonary hypertension subgroups correlate with patient survival.
Koudstaal T, van Uden D, van Hulst JAC, Heukels P, Bergen IM, Geenen LW, Baggen VJM, van den Bosch AE, van den Toorn LM, Chandoesing PP, Kool M, Boersma E, Hendriks RW, Boomars KA. Koudstaal T, et al. Among authors: boersma e. Respir Res. 2021 May 4;22(1):137. doi: 10.1186/s12931-021-01716-w. Respir Res. 2021. PMID: 33947407 Free PMC article.
885 results